215 related articles for article (PubMed ID: 29530101)
81. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
Martini G; Ciardiello D; Famiglietti V; Rossini D; Antoniotti C; Troiani T; Napolitano S; Esposito L; Latiano TP; Maiello E; Del Re M; Lonardi S; Aprile G; Santini D; Masi G; Avallone A; Normanno N; Pietrantonio F; Pinto C; Ciardiello F; Cremolini C; Martinelli E
Cancer Med; 2023 Apr; 12(8):9392-9400. PubMed ID: 36880426
[TBL] [Abstract][Full Text] [Related]
82. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
[TBL] [Abstract][Full Text] [Related]
83. RAS Mutational Status in Advanced Colorectal Adenocarcinoma Treated With Anti-angiogenics: Preliminary Experience With Liquid Biopsy.
DE Santiago BG; López-Gómez M; Delgado-López PD; Gordo AJ; Neria F; Thuissard-Vasallo IJ; Gómez-Raposo C; Tevar FZ; Moreno-Rubio J; Hernández AM; Iglesias I; Casado E
In Vivo; 2021; 35(5):2841-2844. PubMed ID: 34410976
[TBL] [Abstract][Full Text] [Related]
84. The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study.
Tsai HL; Lin CC; Sung YC; Chen SH; Chen LT; Jiang JK; Wang JY
Br J Cancer; 2023 Oct; 129(6):947-955. PubMed ID: 37488448
[TBL] [Abstract][Full Text] [Related]
85. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
86. Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer.
Pan X; Zhang X
Future Oncol; 2020 Jun; 16(18):1289-1299. PubMed ID: 32379501
[No Abstract] [Full Text] [Related]
87. Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies.
Azuara D; Santos C; Lopez-Doriga A; Grasselli J; Nadal M; Sanjuan X; Marin F; Vidal J; Montal R; Moreno V; Bellosillo B; Argiles G; Elez E; Dienstmann R; Montagut C; Tabernero J; Capellá G; Salazar R
Mol Cancer Ther; 2016 May; 15(5):1106-12. PubMed ID: 27037411
[TBL] [Abstract][Full Text] [Related]
88. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
[TBL] [Abstract][Full Text] [Related]
89. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
[TBL] [Abstract][Full Text] [Related]
90. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer.
Siena S; Sartore-Bianchi A; Garcia-Carbonero R; Karthaus M; Smith D; Tabernero J; Van Cutsem E; Guan X; Boedigheimer M; Ang A; Twomey B; Bach BA; Jung AS; Bardelli A
Ann Oncol; 2018 Jan; 29(1):119-126. PubMed ID: 28945848
[TBL] [Abstract][Full Text] [Related]
91. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
92. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
93. Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status.
Thomsen M; Guren MG; Skovlund E; Glimelius B; Hjermstad MJ; Johansen JS; Kure E; Sorbye H; Pfeiffer P; Christoffersen T; Guren TK; Tveit KM
Eur J Cancer; 2017 Aug; 81():26-35. PubMed ID: 28595137
[TBL] [Abstract][Full Text] [Related]
94. Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
Bidard FC; Kiavue N; Ychou M; Cabel L; Stern MH; Madic J; Saliou A; Rampanou A; Decraene C; Bouché O; Rivoire M; Ghiringhelli F; Francois E; Guimbaud R; Mineur L; Khemissa-Akouz F; Mazard T; Moussata D; Proudhon C; Pierga JY; Stanbury T; Thézenas S; Mariani P
Cells; 2019 May; 8(6):. PubMed ID: 31142037
[TBL] [Abstract][Full Text] [Related]
95. Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel.
Sato KA; Hachiya T; Iwaya T; Kume K; Matsuo T; Kawasaki K; Abiko Y; Akasaka R; Matsumoto T; Otsuka K; Nishizuka SS
PLoS One; 2016; 11(1):e0146275. PubMed ID: 26727500
[TBL] [Abstract][Full Text] [Related]
96. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
Hurwitz HI; Yi J; Ince W; Novotny WF; Rosen O
Oncologist; 2009 Jan; 14(1):22-8. PubMed ID: 19144677
[TBL] [Abstract][Full Text] [Related]
97. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients.
Yang YC; Wang D; Jin L; Yao HW; Zhang JH; Wang J; Zhao XM; Shen CY; Chen W; Wang XL; Shi R; Chen SY; Zhang ZT
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29914973
[TBL] [Abstract][Full Text] [Related]
98. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer.
Motobayashi H; Kitahata Y; Okada KI; Miyazawa M; Ueno M; Hayami S; Miyamoto A; Shimizu A; Sato M; Yoshimura T; Nakamura Y; Takemoto N; Nakai T; Hyo T; Matsumoto K; Yamaue H; Kawai M
J Cancer Res Clin Oncol; 2024 Jan; 150(2):35. PubMed ID: 38277079
[TBL] [Abstract][Full Text] [Related]
99. Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer.
Lucchetti D; Zurlo IV; Colella F; Ricciardi-Tenore C; Di Salvatore M; Tortora G; De Maria R; Giuliante F; Cassano A; Basso M; Crucitti A; Laurenzana I; Artemi G; Sgambato A
Sci Rep; 2021 Nov; 11(1):22686. PubMed ID: 34811396
[TBL] [Abstract][Full Text] [Related]
100. Blood-based
Germetaki T; Nicholls C; Adams RA; Braun M; Rogan J; Moghadam S; Lenfert E; Lukas A; Edelstein DL; Jones FS; Saunders MP
Future Oncol; 2020 Oct; 16(28):2177-2189. PubMed ID: 32716216
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
